Mikrogen | GenomeWeb

Mikrogen

The companies are co-developing an assay that differentiates previously infected, seropositive Lyme disease patients from newly infected individuals.

The company has signed an agreement with biopharmaceutical firm SuppreMol to use its UNIarray technology to identify autoantibody signatures of SLE patients enrolled in a phase IIa study of SuppreMol's lead therapeutic SM101.

In separate deals announced this past week, the German biotech firm will distribute assays developed by Asuragen, and co-develop, co-manufacture, and co-market assays with Mikrogen.

The company is collaborating with fellow German biotech firm Mikrogen to identify autoantibody signatures typical of various infectious diseases.

The German firms said this week that they have conducted a feasibility study for identifying autoantibody signatures in infectious diseases that may be useful for future diagnostics.

The firms are working on infectious disease diagnostics using Protagen's UNIarray platform.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.